University of Southern California


COVID-19 Pre-Clinical Therapeutics/Drug and Vaccine Research

To add your information, please fill out this form.
Please look here for a list of potential COVID-19 Collaborators by Area of Expertise.

Paul Bogdan  
Zikun Yang  
Shahin Nazarian  

Exploiting in silico immuno-informatics, we develop an AI framework to predict and select the best vaccine subunits and construct a multi-epitope vaccine for emerging SARS-CoV-2 virus. Learn more.

Michael Bowdish  

Network for Cardiothoracic Surgical Investigations in Cardiovascular Medicine: Mesenchymal Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome

Julio A. Camarero  
Xiaojiang Chen  
Pinghui Feng  

Therapeutic targeting of SARS-CoV-2 main protease with ultrastable microproteins

Preet Chaudhary  

Off-the-shelf cellular immunotherapy for COVID-19

Siyi Chen  

Development of mucosal COVID-19 vaccines

Ya-Wen Chen  

Blocking COVID-19 from entering into lung cells and providing lung cells and organoids for developing drugs for preventing COVID-19 transmission and cytokine storm.

Ya-Wen Chen  

Development of TMPRSS2 antibody as an antiviral treatment for SARS-CoV-2 (COVID-19).

Ya-Wen Chen  

Non-clinical development of monothiol human thioredoxin-1 (ORP100S) as an inhaled treatment for COVID-19 respiratory disease.

Lucio Comai  
Sita Reddy  
Kyung W. Jung  

Identified a library of drug-like compounds to facilitate degradation or inhibit translation of the SARS-CoV-2 RNA genome.

Denis Evseenko  

Developing novel small molecule immunomodulators to inhibit cytokine storm and lung damage in COVID-19 and similar infections.

Pinghui Feng  
Chao Zhang  
Lucio Comai
Sita Reddy
Nicholas Graham

Developing antiviral molecules against COVID-19.

Justin Ichida  

Development of a host PIKFYVE kinase inhibitor for the treatment of COVID-19.

Cheng Ji  

Investigating side effects of antiviral drugs and minimizing them.

Vsevolod Katritch
Stan Louie
Vadim Cherezov  

Prevention and Treatment of COVID-19 Induced Pneumonia by Stimulating the Protective Arm of Angiotensin System

Stan Louie  

Evaluation of Telmisartan for COVID-19 Disease

Keigo Machida  

Drug to reduce SARS-CoV-2-related disease severity induced by alcohol and tobacco

Keigo Machida  

Targeting RNA methyltransferase and entry to derepress anti-SARS-CoV-2 defense

Charles McKenna  

Repurposing potent antiviral agents for COVID-19.

Ann Mohrbacher  

Dasatinib for the treatment of patients with moderate to severe SARS-CoV2 (COVID-19)

Richard Roberts  
Terry Takahashi  

Developing peptide and protein reagents for COVID-19 serological testing and therapeutics.

Pin Wang  

Creating live hybrid viruses toward an effective COVID-19 vaccine.

Yong Zhang  
Heinz-Josef Lenz  
Alan Epstein  

Combating COVID-19 with Novel Vaccines.